Search
for
Sort by
Research 30 of 1000+
- Dutasteride, a novel dual 5-A reductase inhibitor, reduces serum DHT to a greater extent versus finasteride and achieves finasteride maximal reduction in a larger proportion of patients
- Topical MK-386 (M), an inhibitor of 5α-reductase (5αr) type I, suppresses sebum dht.
- Litigation associated with 5-alpha-reductase-inhibitor use: A Canadian legal database review.
- Nonsteroidal inhibitors of human type I steroid 5-.alpha.-reductase
- Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts
- Selective non-steroidal inhibitors of 5α-reductase type 1
- Aromatase-independent testosterone conversion into estrogenic steroids is inhibited by a 5α-reductase inhibitor
- Novel inhibitors of 5α-reductase
- Aromatase inhibitors induce ‘male pattern hair loss’ in women?
- Pharmacophore and Atom Based 3D QSAR Studies on the Novel 5-Alpha-Reductase Inhibitors
- Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
- SAT-288 Successful Virilization of a PAIS Patient with a Missense Mutation In The Ligand-binding Domain Of The Androgen Receptor with Combined High-dose Testosterone and Aromatase Inhibitor
- Androgens inhibit phagocytosis by macrophages via the androgen receptor in vitro
- Natural Product-Inspired Bis(trifluoromethyl) Phenyl Hydroxycinnamate Derivatives as Promising Nonsteroidal Inhibitors of Human Steroid 5α-Reductase Type-1: Synthesis, <i>In Vitro</i>, and <i>In Silico</i> Studies
- Antiandrogens and Androgen Inhibitors
- A Narrowed Look Into Plant-Derived Testosterone 5α-Reductase Inhibitors for Androgenetic Alopecia
- FCE 28260, a new 5α-reductase inhibitor: In vitro and in vivo effects
- The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications
- COMBINATION OF AN ANTIANDROGEN AND A 5α-REDUCTASE INHIBITOR: A FURTHER STEP TOWARDS TOTAL ANDROGEN BLOCKADE?
- Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor
- DIHYDROTESTOSTERONE AND THE PROSTATE: THE SCIENTIFIC RATIONALE FOR 5α-REDUCTASE INHIBITORS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
- An overview on 5α-reductase inhibitors
- Effects of Finasteride (MK-906), a 5<i>α</i>-Reductase Inhibitor, on Circulating Androgens in Male Volunteers*
- Effect of Testosterone Supplementation With and Without a Dual 5α-Reductase Inhibitor on Fat-Free Mass in Men With Suppressed Testosterone Production
- External genitalia abnormalities in male rats exposed in utero to finasteride, a 5α-reductase inhibitor
- A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α-reductase inhibitors GI198745 and finasteride
- Effects of the 5α-Reductase Inhibitor Finasteride on Serum Levels of Gonadal, Adrenal, and Hypophyseal Hormones and its Clinical Significance: A Prospective Clinical Study
- Nipple Differentiation in Fetal Male Rats Treated with an Inhibitor of the Enzyme 5<i>α</i>-Reductase: Definition of a Selective Role for Dihydrotestosterone*
- Inhibitors of 5α-Reductase in the Treatment of Benign Prostatic Hyperplasia
- Actions of 5α-reductase inhibitors on the epididymis